Inhibrx Biosciences
INBX
93.36
-0.05
-0.05%
Inhibrx Biosciences
US · INBX
#3022 by market cap
Listed 2024
93.36
-0.05
-0.05%
Live - 5344 symbols - heartbeat 444s ago
· 2026-10-07 19:54
After-hours
93.41
+0.05%
- Market cap
- 1.37B
- P/E (TTM)i
- -10.51
- P/Bi
- -25.93
- EPSi
- -9.04
- Div yieldi
- 0.00%
- 52W posi
- 51%
Reader sentiment
Are you bullish or bearish on INBX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.38, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Latest year +550.00% YoY
Margins
- Operating margin
- -10,386.54%
- Net margin
- -10,773.46%
Key ratios & quality
- Enterprise valuei
- 1.35B
- Altman Z-Scorei
- 1.38
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 1.32M | 1.80M | 200.00K | 1.30M |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 15.04M | 29.38M | 127.50M | 23.12M |
| Research & development | 101.60M | 191.64M | 203.74M | 113.03M |
| Operating profit | -115.32M | -219.22M | -331.45M | -135.03M |
| Pretax profit | -115.32M | -239.72M | 1.69B | -140.05M |
| Tax | 3.00K | 3.00K | 2.00K | 2.00K |
| Net profit | -115.33M | -241.36M | 1.69B | -140.06M |
| Basic EPS | -8 | -17 | 114 | -9 |
| Diluted EPS | -8.10 | -16.95 | 112.62 | -9.04 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | 1.30M | 0 | 0 | -- | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 6.02M | 6.42M | 5.28M | 5.40M | 5.71M | 8.25M |
| Research & development | 36.88M | 22.27M | 28.54M | 25.35M | 25.22M | 23.90M |
| Operating profit | -42.90M | -27.39M | -33.81M | -30.92M | -30.93M | -32.15M |
| Pretax profit | -43.31M | -28.65M | -35.26M | -32.83M | -33.44M | -36.65M |
| Tax | 0 | 2.00K | 0 | 0 | 0 | 3.00K |
| Net profit | -43.31M | -28.65M | -35.26M | -32.83M | -33.44M | -36.65M |
| Basic EPS | -3 | -2 | -2 | -2 | -2 | -2 |
| Diluted EPS | -2.80 | -1.85 | -2.28 | -2.11 | -2.15 | -2.34 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 6.26M | 295.36M | 160.40M | 132.83M |
| Cash & ST investments | -- | 277.92M | 152.60M | 124.22M |
| Inventory | -- | -- | -- | -- |
| Total assets | 16.65M | 307.89M | 180.77M | 146.48M |
| Total current liabilities | 20.77M | 56.31M | 40.73M | 33.80M |
| Short-term debt | 1.86M | 2.06M | 1.60M | 2.33M |
| Long-term debt | -- | 206.97M | -- | 100.56M |
| Total liabilities | 23,945,000.00 | 264,390,000.00 | 47,183,000.00 | 138,485,000.00 |
| Total equity | -7.30M | 43.50M | 133.58M | 7.99M |
| Retained earnings | -- | -613.73M | -106.13M | -246.19M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 223.39M | 193.96M | 161.42M | 132.83M | 171.34M | 142.21M |
| Cash & ST investments | 216.52M | 186.57M | 153.09M | 124.22M | 161.66M | 133.34M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 242.64M | 212.12M | 177.47M | 146.48M | 183.97M | 154.22M |
| Total current liabilities | 43.64M | 38.94M | 35.98M | 33.80M | 26.51M | 28.06M |
| Short-term debt | 1.97M | 2.17M | 2.25M | 2.33M | 2.41M | 2.49M |
| Long-term debt | 98.65M | 99.28M | 99.92M | 100.56M | 174.99M | 176.29M |
| Total liabilities | 148,196,000.00 | 143,559,000.00 | 140,641,000.00 | 138,485,000.00 | 205,002,000.00 | 207,199,000.00 |
| Total equity | 94.44M | 68.56M | 36.83M | 7.99M | -21.04M | -52.98M |
| Retained earnings | -149.44M | -178.10M | -213.35M | -246.19M | -279.63M | -316.28M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -90.81M | -193.31M | -194.41M | -129.79M |
| Depreciation & amortization | 1.23M | 1.19M | 2.29M | 2.48M |
| Free cash flow | -91.50M | -197.90M | -197.01M | -129.83M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 200.00M | -- | -- |
| Ending cash balance | 0 | 277.92M | 152.60M | 124.22M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -35.90M | -29.95M | -33.82M | -30.12M | -38.03M | -29.92M |
| Depreciation & amortization | 675.00K | 661.00K | 583.00K | 564.00K | 537.00K | 523.00K |
| Free cash flow | -35.92M | -29.95M | -33.83M | -30.12M | -38.03M | -29.92M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 216.52M | 186.57M | 153.09M | 124.22M | 161.66M | 133.34M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | 2,686.98 | -197.85 |
| ROA %i | -692.85 | -726.76 | 1,632.34 | -85.60 |
| ROIC %i | -- | -- | 2,470.36 | -106.29 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -8,864.18 | -9,348.04 | 850,532.50 | -9,835.15 |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | 0.30 | 5.25 | 3.94 | 3.93 |
| Quick ratioi | 0.01 | 4.95 | 3.76 | 3.68 |
| Debt / assetsi | 30.24 | 68.25 | 4.45 | 73.06 |
| LT debt / equityi | -- | 478.31 | 4.83 | 1,309.72 |
| Interest coveragei | -- | -- | 126.09 | -10.48 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -0.03 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 4,118.34 | -113.71 | -144.07 | -197.85 | -354.69 | -1,773.60 |
| ROA %i | 1,272.22 | -69.58 | -77.54 | -85.60 | -61.03 | -75.44 |
| ROIC %i | 1,784.58 | -83.89 | -95.34 | -106.29 | -69.90 | -86.88 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 865,511.50 | -11,275.86 | -10,433.79 | -9,835.15 | -9,012.85 | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 5.12 | 4.98 | 4.49 | 3.93 | 6.46 | 5.07 |
| Quick ratioi | 4.97 | 4.82 | 4.28 | 3.68 | 6.10 | 4.76 |
| Debt / assetsi | 43.90 | 50.34 | 60.24 | 73.06 | 98.33 | 117.77 |
| LT debt / equityi | 110.71 | 152.60 | 284.17 | 1,309.72 | -- | -- |
| Interest coveragei | 215.03 | -27.08 | -16.21 | -10.48 | -9.00 | -7.88 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Drug discovery and development activities through conducting preclinical studies and clinical trials100.00%
Region
United States100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.